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Abstract
Background: Dealing with heterogeneity in meta-analyses is often tricky, and there is only limited advice for
authors on what to do. We investigated how authors addressed different degrees of heterogeneity, in particular
whether they used a fixed effect model, which assumes that all the included studies are estimating the same true
effect, or a random effects model where this is not assumed.
Methods: We sampled randomly 60 Cochrane reviews from 2008, which presented a result in its first meta-analysis
with substantial heterogeneity (I
2 greater than 50%, i.e. more than 50% of the variation is due to heterogeneity
rather than chance). We extracted information on choice of statistical model, how the authors had handled the
heterogeneity, and assessed the methodological quality of the reviews in relation to this.
Results: The distribution of heterogeneity was rather uniform in the whole I
2 interval, 50-100%. A fixed effect
model was used in 33 reviews (55%), but there was no correlation between I
2 and choice of model (P = 0.79). We
considered that 20 reviews (33%), 16 of which had used a fixed effect model, had major problems. The most
common problems were: use of a fixed effect model and lack of rationale for choice of that model, lack of
comment on even severe heterogeneity and of reservations and explanations of its likely causes. The problematic
reviews had significantly fewer included trials than other reviews (4.3 vs. 8.0, P = 0.024). The problems became less
pronounced with time, as those reviews that were most recently updated more often used a random effects
model.
Conclusion: One-third of Cochrane reviews with substantial heterogeneity had major problems in relation to their
handling of heterogeneity. More attention is needed to this issue, as the problems we identified can be essential
for the conclusions of the reviews.
Background
Variability among individual study results in systematic
reviews virtually always occurs. This is caused partly by
random error (chance) and partly by systematic differ-
ences between the trials. The variation in the true
effects is called heterogeneity. Its impact on meta-ana-
lyses can be assessed by I
2 that describes the percentage
of the variability that is due to heterogeneity [1,2].
Values greater than 50% are - rather arbitrarily - consid-
ered substantial heterogeneity [1].
Strategies for addressing heterogeneity in systematic
reviews include checking that the data extracted from
the trial reports are correct, which may often not be the
case [3]; omitting meta-analysis; conducting subgroup
analysis or meta-regression; choosing a fixed effect or a
random effects model [2]; changing the statistical
metric, e.g. from a risk difference to a relative risk [4,5];
and excluding studies.
The fixed effect model assumes that all the included
studies are estimating the same true effect. The variation
in findings among studies is therefore due to chance [2].
Each study will be assigned a weight depending on the
study’s precision (within-trial variance) and an overall
estimate can be calculated. Small studies will contribute
relatively little to the outcome because they have less
precision [6].
The random effects model assumes that the effects
being estimated in the different studies are not identical,
but follow a distribution. The confidence interval takes
account of the additional uncertainty in the location of
the mean of the systematically different effects in the
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any medium, provided the original work is properly cited.different studies (this between-trial variance is added to
the within-trial variance). Small studies will therefore
contribute more to the average than in a fixed effect
analysis, which is reasonable because the studies repre-
sent different true effects. Thus, when heterogeneity is
present, the confidence interval around a random effects
pooled estimate is wider than a confidence interval
around a fixed effect pooled estimate [6].
Dealing with heterogeneity is often tricky, and there is
only limited advice for authors on what to do, e.g. on
when a particular model should be chosen for the other
[7], or when the heterogeneity becomes too large for a
meaningful meta-analysis.
An additional complexity is that the test for detecting
heterogeneity has low power when the sample sizes are
small or when few trials are included. For example, 11
trials give just 10 degrees of freedom, like a t-test on
two groups of 6 people each does. There is also varia-
tion in practice as to which P-value demonstrates signif-
icant heterogeneity [2], but as the power of the test is so
low, it is common to choose P = 0.10. It is important to
be aware, however, that the choice of statistical model
should not be based on the outcome of a test of hetero-
geneity [2].
The aim of our study was to investigate how authors
address different degrees of substantial heterogeneity in
meta-analyses in Cochrane reviews.
Methods
We listed all Cochrane reviews from the Cochrane Data-
base of Systematic Reviews 2008, Issue 1, which had at
least one meta-analysis and where the first outcome in
the first comparison involved all studies (’total’), and not
only subgroups of studies (’subtotals’). We assumed that
in most cases the first outcome in the first comparison
would be the primary outcome and that in the remainder,
it would still be important for the review.
There were 3,385 Cochrane reviews, and of these,
2,354 (70%) had a least one meta-analysis, and 1,366
(40%) had a ‘total’ for the first outcome. Figure 1 shows
that the distribution of I
2 for the 1,366 meta-analyses
was rather uniform, apart from a decline in numbers of
reviews with the most extreme degrees of heterogeneity
and a large number of reviews in the group with I
2 of
0%. The latter result is expected since the calculation of
I
2 gives many negative values, in which case I
2 is by
definition set to zero [1].
Because of the relatively smooth distribution, we ran-
domly selected 60 reviews with an I
2 of more than 50%
for our study, using the random numbers generator in
Excel. After having assessed the 60 reviews, it was clear
that we had enough information to elucidate how
authors address different degrees of substantial
heterogeneity.
For every review, one observer (JBS) copied the relevant
data into an Excel spreadsheet and a second observer
(PCG) checked the data. Disagreements were few and
were resolved by discussion. The extracted data were:
i) The selected statistical model (random or fixed);
ii) Any rationale for choosing the model; iii) The critical
value for considering heterogeneity statistically signifi-
cant; iv) Reservations about the results in relation to
choice of model and comments on the heterogeneity;
v) Attempts at explaining the heterogeneity narratively,
e.g. different doses, populations, length of follow-up or
quality of the included studies; vi) Attempts at addressing
the heterogeneity statistically, e.g. by division of studies
in subgroups, test for interaction, sensitivity analysis with
omission of some studies, or meta-regression; this infor-
mation was extracted from the Results section and in
some cases directly from the graphs; vii) Point estimate
and its P-value; the point estimate was also calculated
with the alternative effect model, using the built-in facil-
ity for this in The Cochrane Library; viii) The P-value
for the chi-square test for heterogeneity.
We assessed the overall methodological quality of the
review based on whether the above points were
a d d r e s s e da ta l la n df o c u s i n go ni ft h e r ew e r em a j o r
problems in handling and interpretation of heterogene-
ity. We decided ap r i o r ithat using a random effects
model was a reasonable way of addressing substantial
heterogeneity (unless there were special circumstances,
as discussed below), and our assessments therefore
focused mostly on those reviews where the authors
h a du s e daf i x e de f f e c tm o d e lo rw h e r eo n l yo n eo ft h e
two models yielded a statistically significant estimate.
We strived to be conservative in our judgments. If,
for example, the authors had used a fixed effect model
and gave the result of the heterogeneity test in the
Results section, we interpreted this as a reservation
about the result in relation to choice of model even if
the authors provided no comments. Similarly, when a
random effects model was chosen we interpreted this as
a reservation.
We investigated whether the choice of model
depended on the degree of heterogeneity, or on the P-
value for the heterogeneity test. We did this because the
reviews were produced at different times. Before the I
2
was developed, authors often relied on the P-value to
identify heterogeneity [1].
Results
Choice of model in relation to degree of heterogeneity
Several of the 60 selected reviews had been published
more than once. The oldest was most recently updated
in 1996 and the newest in 2007 (median 2005). A fixed
effect model was used in 33 reviews (55%), and a ran-
dom effects model in 27 reviews (the Cochrane software
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tion between degree of heterogeneity and choice of
model (Figure 2, P = 0.79, Mann-Whitney test for trend,
with correction for ties), in fact the average I
2 was 71%,
both for reviews using a fixed effect model and for
those using a random effects model.
The authors selected the random effects model more
often in the newest half of the reviews (updated later
than 1 June 2005, Table 1), than in the oldest half. The
same pattern was evident for the subgroup of reviews
with marginally statistically significant heterogeneity (P-
value between 0.05 and 0.10, P = 0.007, Fisher’s exact
test).
Significant effects in relation to choice of model
A significant effect estimate (P < 0.05) was presented in
34 reviews. For 6 of the 60 reviews, a significant result
changed to a non-significant result when we applied the
Figure 1 Frequency distribution of Cochrane reviews in relation to I
2 for the first outcome in the first comparison.
Figure 2 Choice of model, reviews grouped by I
2.
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reviews, a non-significant result became significant
when we used the alternative model (Table 2). These 5
reviews had all used a random effects model and
addressed heterogeneity this way; they were free of
major methodological problems and will therefore not
be discussed further.
F o r2o ft h e6r e v i e w s[ 9 , 1 0 ]w h e r eas i g n i f i c a n tr e s u l t
changed to a non-significant when we used a random
effects model, the authors were cautious about their het-
erogeneous result and didn’t base their conclusion on the
significant finding they had o b t a i n e dw i t haf i x e de f f e c t
model, which we consider a correct approach. One
review was explicit about this: “Substantial heterogeneity
was also detected (p = 0.03, I
2 = 79%). Because of this, the
result of this analysis should be interpreted with caution
and not be considered a definitive statement” [10].
The authors of the other 4 reviews were less cautious.
One review [11] calculated mean differences instead of
standardized mean differences, although the outcomes
were measured on very different scales. Because of this
error, both the means and the standard deviations dif-
fered by a factor of 10. This resulted in extreme hetero-
geneity (I
2 = 93%, P = 0.0002) despite very low power,
as only two studies were included. In the methods sec-
tion, the authors promised to use a random effects
model in case of heterogeneity, but this was not done
(and would not have solved the other problem).
In another review [12], the authors calculated the
standardized mean difference both with a fixed effect
model (1.07, 95% confidence interval 0.43 to 1.70) and a
random effects model (1.74, -0.71 to 4.19). In the meth-
ods section, they stated they would use a random effects
model if heterogeneity was present, which it was (I
2 =
89%, P = 0.002). With a random effects model, the
result was not significant. They wrote that no definite
conclusion could be made but added that there was rea-
sonable evidence that cognitive therapy was beneficial in
treating depression. We find this conclusion doubtful,
given the data and their declared methods. In this exam-
ple, the effect estimate calculated by the two models
differs substantially due to a one small outlying study.
Hence, the choice of model should have been consid-
ered and explained in detail.
Another review [13] used Peto’s odds ratio (0.28, 0.11
to 0.73). Significant heterogeneity was present (I
2 = 59%,
P = 0.05), and when using the ordinary odds ratio and a
random effects model, the result became 0.28 (0.05 to
1.55). The authors concluded in the abstract that albu-
min showed a clear benefit at preventing severe ovarian
hyperstimulation syndrome, although they were much
more cautious in the main text.
The authors of the last review [14] reported that the
P-value for heterogeneity was insignificant even
though it was 0.07 and the power of the heterogeneity
t e s tw a sv e r yl o w ,a st h e r ew e r eo n l y5s t u d i e s .T h e y
reported less mortality in the intervention group, rela-
tive risk 0.86 (0.74 to 1.00). With a random effects
model the relative risk became 0.82 (0.57 to 1.18),
with P = 0.30. The authors mentioned that heteroge-
neity was present and noted that one outlying trial
had a very low mortality in the control group. The
meta-analysis was driven by a big trial, which com-
prised 69% of the deaths and showed the same result
as the pooled result, 0.86 (0.75 to 1.00). Even so, we
find it pretty bold that the authors believed in a result
with borderline significance (P = 0.05), and only when
using the fixed effect model, with so much heteroge-
neity, and with unexplained discrepancies between
the results of the trials.
Cautions about the heterogeneity
In our judgment, 40 of the 60 reviews were devoid of
major problems in relation to their handling of hetero-
geneity (Table 3). However, only 27 reviews (45%) gave
a rationale for choice of statistical model. Our overall
judgment of methodological quality was not related to
I
2 (P = 0.26, Mann-Whitney test for trend corrected for
ties, grouping I
2 into intervals of 10%). However, the
unproblematic reviews contained more studies than pro-
blematic reviews, 8.0 versus 4.3, on average (P = 0.024,
student t-test, two-tailed).
Table 1 Choice of model in relation to the P-value for the
heterogeneity test
Newer reviews Older reviews
P Random Fixed Random Fixed
< 0.0001 60 26
[0.0001;0.001[ 21 21
[0.001;0.01[ 12 03
[0.01;0.05[ 74 14
[0.05;0.1[ 62 08
> = 0.1 00 02
Total 22 9 5 24
Newer reviews are those updated after 1 June 2005 (n = 31). P = 0.007 for
those reviews where the heterogeneity test yielded a P-value between 0.05
and 0.10.
Table 2 Results using the authors’ model and the
alternative model we applied
Authors’ model
Significant Non-
significant
Total
Alternative
model
Significant 28 5 33
Non-
significant
62 1 2 7
Total 34 26 60
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fixed effect model. There can be plausible reasons for
this, even in cases with substantial heterogeneity, but
authors should then explain what they are. Eight of
these 20 reviews had no explanations or reservations
and did not address the heterogeneity statistically
[15-22]. One review [21] had only included one study,
but the patients were split into two subgroups, accord-
ing to whether they had a rash. Both results were signif-
icant, but one showed harm and the other benefit
(Figure 3). Combining such results is inappropriate and
doesn’t represent today’s standards of Cochrane reviews
(the review was last updated in 1996).
Five other reviews used Peto’s odds ratio
[23,24,13,18,19], and three reviews didn’t follow the ana-
lysis plan that was set out in the methods section
[12,25,26], which included using a random effects model
or omitting meta-analysis in case of heterogeneity, and
there was no explanation why. Three other reviews paid
no attention to the heterogeneity and didn’t discuss it,
even though the P-value was between 0.05 and 0.10
[27,14,28]. An additional review described the heteroge-
neity (I
2 = 71%, P = 0.06) but ignored it due to “lack of
stability of the known tests” [29], which is not a valid
reason for ignoring heterogeneity. In another review, the
authors divided the analysis into subgroups because they
had found heterogeneity, but although the consequence
was that the chi-square test for heterogeneity was no
longer significant due to loss of power, the I
2 actually
increased, which the authors failed to comment on [30].
In yet another review, which was discussed above, the
authors pooled two risk scores measured on different
scales that varied by a factor of ten [11]. The complete
list of included reviews can be found on the web http://
sites.google.com/site/dealingwithheterogeneity/.
Discussion
It can be challenging to choose the most appropriate
model for meta-analysis, as there are pros and cons with
both models [2]. It is pretty clear that the larger the het-
erogeneity, the harder it is to defend choosing a fixed
effect model, as different studies cannot be assumed to
provide estimates of a common, true effect. However,
one also needs to consider that a random effects model
may apply too much weight to small studies, which are
often poorly done and biased. An example is shown in
Figure 4, where it appeared reasonable that the authors
used a fixed effect model despite pronounced heteroge-
neity, as it gives more weight to the only large study,
which, moreover, had a result that was closer to no
effect than most other studies. It is also possible that
the studies were so different that they should not have
been combined in a meta-analysis. Only a closer look at
the review, and possibly also at the individual studies,
can elucidate this, and even then, researchers may dis-
agree what would be the most appropriate approach.
It is also important to consider that the fixed effect
model only allows an inference about the studies
included in the meta-analysis, whereas the random
effects model allows an inference about the mean effect
in a hypothetical population of studies if we can assume
that the studies included in the meta-analysis constitute
Table 3 Our assessments of the 60 reviews in relation to
their handling of heterogeneity
Reviews Per
cent
Overall acceptable methodological quality 40 (67%)
Rationale given for choice of model 27 (45%)
Valid reservations against results 36 (60%)
Explanation of causes of heterogeneity 40 (67%)
Explanation reasonable 36 (60%)
Heterogeneity addressed statistically in the
analysis
39 (65%)
Figure 3 Extremely diverging results. Both results originate from the same study [21].
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population.
The random effects model is more conservative than
the fixed effect model in the sense that the confidence
interval is broader, but sometimes the point estimate is
farther from the null and the P value for the pooled
effect smaller than with a fixed effect model [31].
When using a random effects model, the between-
study variance needs to be calculated, but if there are
few studies, this cannot be calculated with any precision,
and a fixed effect model is therefore sometimes used in
this situation [6].
It was surprising that we did not find a relation
between the degree of heterogeneity and the choice of
model. Some Cochrane groups instruct their authors to
routinely use a fixed effect model, although few statisti-
cians would find such blanket recommendations reason-
able. Furthermore, in all types of research, authors
should change their planned analysis and explain why if
it would not be sensible.
Readers might be more willing to accept the results if
they are robust to both types of analyses, but we found
only one example of this approach [32]. Authors should
also consider the possibility of abstaining from meta-ana-
lysis and explore the reasons for the heterogeneity instead,
and we identified several reviews where this might have
been better. For example, one review with extreme hetero-
geneity (I
2 = 98%, P < 0.0001) pooled three trials with a
random effects model although none of them had overlap-
ping confidence intervals (Figure 5) [20].
Although our sample consisted only of reviews with
substantial heterogeneity, about a third of the authors
had not paid any attention to it. This omission was
q u i t eu n i f o r mo v e rt h es p e c t r u mo fI
2 values, and it
might therefore partly reflect the well-known lack of sta-
tistical skills among authors of medical research papers
[33-35]. However, as authors are recommended to routi-
nely assess whether the results are consistent across stu-
dies [2], and what the likely causes are if they are not,
they could do better even without having access to sta-
tistical expertise. Cochrane review groups could also do
better, as they are required to have access to statistical
expertise [2]. Recently, summary of findings tables were
introduced in Cochrane reviews as part of GRADEprofi-
ler, where the authors are asked to assess the quality of
the body of evidence. This includes assessing the likeli-
hood that the pooled estimate for each outcome is free
from bias [2], and a judgment related to the degree of
heterogeneity.
Reviews that were devoid of major problems had
included more trials than those with problems. The
likely reason for this is that authors are usually too
influenced by whether or not a P-value is significant and
often do not take into account, or do not know, that P-
values depend on the number of trials. When fewer
trials are included, it is harder to identify heterogeneity
using a chi-square test. This test is therefore not the
recommended way to investigate heterogeneity [1]. I
2 is
more sensitive but with few included trials there is a
small risk of false positives.
Figure 4 Results analysed using a fixed effect model, which gives more weight to the only large study [22].
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Our sampling method precludes us from drawing gen-
eral conclusions about the quality of Cochrane reviews
in relation to heterogeneity. As we sampled meta-
analyses, we did not assess how often the authors had
abstained from pooling the results because of heteroge-
neity, which would have been an arduous task, given
our total sample of 3,385 reviews.
The most important assessment - whether a review
was devoid of major problems related to heterogeneity -
was not as thoroughly specified in our protocol as we
would have wished. It would not have been possible to
specify in advance rigid rules because of the great diver-
sity in handling and reporting heterogeneity. We have
compensated for this limitation by describing the pro-
blematic reviews we encountered. More strict criteria
could be used in future studies based on our findings.
In a few reviews, our outcome was not a primary one,
which could be the reason that the heterogeneity was
not addressed. On the other hand, these reviews tended
to not address heterogeneity at all, for any outcomes.
We specified in our protocol that we wanted to investi-
gate to which extent the point estimates and the confi-
dence interval varied when a different model was chosen,
but decided to focus on reviews where the result changed
from significant to nonsignificant and vice versa.
Some of our analyses were exploratory. During data
extraction, we decided to investigate if there was a rela-
tion between the choice of model and the P-value for
heterogeneity, and we couldn’t help noticing that the
reviews we judged to be most problematic also tended
to be those that had included fewest trials.
It is known that I
2 increases when the sizes of the
included studies increase and alternative measures of
heterogeneity have been suggested [36]. However, the
problematic reviews identified in our study included
very few trials and relatively few participants. When
there are only few included trials there is a small risk of
I
2 above 50% even though no heterogeneity is present.
Other studies of heterogeneity
In the early years of the Cochrane Collaboration, ran-
domly selected Cochrane reviews were assessed by two
different observers, and 29% were judged to have major
problems [37], but these concerned other issues than
heterogeneity. In another study of Cochrane reviews,
heterogeneity, defined as P < 0.10, was identified in 34
out of 86 meta-analyses, and in 12 of the 34 meta-ana-
lyses, heterogeneity was not addressed [38]. In 2002,
Higgins et al. [7] investigated the newest Cochrane
reviews and tested if heterogeneity was present, and col-
lected information about choice of model and subgroup
analyses. The study compared the protocol to the review
and identified problems concerning choice of statistical
model and problems with conducting subgroup analyses,
as there were often too few included trials.
Conclusion
One-third of Cochrane reviews with substantial hetero-
geneity in the first reported outcome had major pro-
blems in relation to their handling of heterogeneity.
These consisted mainly of the use of a fixed effect
model without an explicit rationale for choice of that
model, and lack of reservations and explanations of the
likely causes of the heterogeneity. These problems
became less pronounced with time, as those reviews
that were most recently updated much more often used
a random effects model. More attention is needed to
this issue, as the problems we identified can be essential
for the conclusions of the reviews.
Figure 5 Example of extreme heterogeneity [20].
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